Floatz logo

Epirubicin

Gastrointestinal Stromal Tumor (GIST)

Daiichi SankyoPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Gastrointestinal Stromal Tumor (GIST) cohort.

Asset / SponsorPhaseRating
Pexidartinib
Daiichi Sankyo
Phase 1/2CCC
Pembrolizumab
Daiichi Sankyo
Phase 1/2CCC
Cyclophosphamide
Daiichi Sankyo
Phase 1/2CCC
Eloxatin
TG Therapeutics, Inc.
Phase 1CC
Olverembatinib
Ascentage Pharma Group Inc.
Phase 1CC
Umbralisib
TG Therapeutics, Inc.
Phase 1C

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →